FluoGuide AS Ordinary Shares FLUO
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- SEK 33.00
- Day Range
- SEK 31.00–35.30
- 52-Week Range
- SEK 28.00–47.80
- Bid/Ask
- SEK 31.70 / SEK 31.90
- Shares Outstanding
- 16.35M
- Market Cap
- SEK 518.27M
- Volume/Avg
- 12,093 / 6,499
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
FluoGuide AS is a clinical-stage biotechnology company focused on developing drugs that maximize surgical outcomes by making cancer fluorescent. Its technology includes uPAR, which is part of a proteolytic system, and FG001, a product injected into the patient's vein prior to surgery.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 7
- Website
- https://www.fluoguide.com
Valuation
|
Metric
|
FLUO
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 11.38 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
FLUO
|
|---|---|
Quick Ratio | 1.80 |
Current Ratio | 1.88 |
Interest Coverage | −8.56 |
Quick Ratio
FLUO
Profitability
|
Metric
|
FLUO
|
|---|---|
Return on Assets (Normalized) | −79.13% |
Return on Equity (Normalized) | −175.46% |
Return on Invested Capital (Normalized) | −78.96% |
Return on Assets
FLUO
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|$BfH&h | LOCK|tHx#S | $129B | |||
| Moderna Inc
MRNA
| LOCK|$mX#&g< | LOCK|^T | $90B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|GT^^v#p | LOCK|pn>> | $77B | |||
| argenx SE ADR
ARGX
| LOCK|@&&@w& | LOCK|XXm | $51B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|$C&j?wc | LOCK|T%s | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|%@gm%#y | LOCK|%c>s | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|FHJG?ht | LOCK|TjG>Q | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|kWP@>^T | LOCK|X^ | $24B | |||
| Incyte Corp
INCY
| LOCK|&m?>#>S | LOCK|$>^ | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|>!#hN@ | LOCK|&%z | $14B |
United States